Literature DB >> 9032281

Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2.

C S Duckett1, R W Gedrich, M C Gilfillan, C B Thompson.   

Abstract

CD30 is a lymphoid cell-specific surface receptor which was originally identified as an antigen expressed on Hodgkin's lymphoma cells. Activation of CD30 induces the nuclear factor kappaB (NF-kappaB) transcription factor. In this study, we define the domains in CD30 which are required for NF-kappaB activation. Two separate elements of the cytoplasmic domain which were capable of inducing NF-kappaB independently of one another were identified. The first domain (domain 1) mapped to a approximately 120-amino-acid sequence in the membrane-proximal region of the CD30 cytoplasmic tail, between residues 410 and 531. A second, more carboxy-terminal region (domain 2) was identified between residues 553 and 595. Domain 2 contains two 5- to 10-amino-acid elements which can mediate the binding of CD30 to members of the tumor necrosis factor receptor-associated factor (TRAF) family of signal transducing proteins. Coexpression of CD30 with TRAF1 or TRAF2 but not TRAF3 augmented NF-kappaB activation through domain 2 but not domain 1. NF-kappaB induction through domain 2 was inhibited by coexpression of either full-length TRAF3 or dominant negative forms of TRAF1 or TRAF2. In contrast, NF-kappaB induction by domain 1 was not affected by alterations in TRAF protein levels. Together, these data support a model in which CD30 can induce NF-kappaB by both TRAF-dependent and -independent mechanisms. TRAF-dependent induction of NF-kappaB appears to be regulated by the relative levels of individual TRAF proteins in the cell.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032281      PMCID: PMC231879          DOI: 10.1128/MCB.17.3.1535

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

Review 1.  The tumor necrosis factor ligand and receptor families.

Authors:  F Bazzoni; B Beutler
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

2.  I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction.

Authors:  M Rothe; J Xiong; H B Shu; K Williamson; A Goddard; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

3.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells.

Authors:  G Nabel; D Baltimore
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

4.  The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression.

Authors:  J A Gross; T St John; J P Allison
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

5.  CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.

Authors:  C A Smith; H J Gruss; T Davis; D Anderson; T Farrah; E Baker; G R Sutherland; C I Brannan; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

6.  Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3).

Authors:  C S Duckett; N D Perkins; T F Kowalik; R M Schmid; E S Huang; A S Baldwin; G J Nabel
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

7.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.

Authors:  H Stein; D Y Mason; J Gerdes; N O'Connor; J Wainscoat; G Pallesen; K Gatter; B Falini; G Delsol; H Lemke
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

8.  Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B.

Authors:  L Osborn; S Kunkel; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

9.  Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.

Authors:  H Dürkop; U Latza; M Hummel; F Eitelbach; B Seed; H Stein
Journal:  Cell       Date:  1992-02-07       Impact factor: 41.582

Review 10.  The scanning model for translation: an update.

Authors:  M Kozak
Journal:  J Cell Biol       Date:  1989-02       Impact factor: 10.539

View more
  65 in total

1.  Regulation of CD30 antigen expression and its potential significance for human disease.

Authors:  M E Kadin
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene.

Authors:  E J Croager; A M Gout; L J Abraham
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

3.  Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells.

Authors:  Ryouichi Horie; Takuro Watanabe; Kinji Ito; Yasuyuki Morisita; Mariko Watanabe; Takaomi Ishida; Masaaki Higashihara; Marshall Kadin; Toshiki Watanabe
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 4.  Prognostic factors in pediatric Hodgkin disease.

Authors:  Cindy L Schwartz
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

5.  A novel role for XIAP in copper homeostasis through regulation of MURR1.

Authors:  Ezra Burstein; Lakshmanan Ganesh; Robert D Dick; Bart van De Sluis; John C Wilkinson; Leo W J Klomp; Cisca Wijmenga; George J Brewer; Gary J Nabel; Colin S Duckett
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

6.  TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40.

Authors:  Aristides G Eliopoulos; Elyse R Waites; Sarah M S Blake; Clare Davies; Paul Murray; Lawrence S Young
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 7.  Brentuximab vedotin.

Authors:  Niels W C J van de Donk; Eugen Dhimolea
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 8.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 9.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

10.  A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.

Authors:  Wei Wei; Yuquan Lin; Zhihui Song; Wenming Xiao; Liqi Chen; Jiejing Yin; Yan Zhou; Stefan K Barta; Michael Petrus; Thomas A Waldmann; Yibin Yang
Journal:  Clin Cancer Res       Date:  2020-04-16       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.